- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ajanta Pharma Q3 net up 20 Percent at Rs 111.3 crore
New Delhi : Ajanta Pharma reported a 19.60 per cent increase in consolidated net profit at Rs 111.3 crore for the quarter ended December 31, 2015.
The company had posted a net profit of Rs 93.06 crore for the same period of the previous fiscal.
Net sales of the company rose to Rs 465.71 crore for the December quarter, up 15.97 per cent from Rs 401.56 crore in the year-ago period, Ajanta Pharma said in a BSE filing.
"We have established strong sales and marketing network in select international markets which continue to perform well and generate demand for our branded generics.
"However, the currency devaluation and scarcity of forex availability in few emerging markets limited us to achieve our full potential," Ajanta Pharma Joint Managing Director Rajesh Agrawal said.
The company had posted a net profit of Rs 93.06 crore for the same period of the previous fiscal.
Net sales of the company rose to Rs 465.71 crore for the December quarter, up 15.97 per cent from Rs 401.56 crore in the year-ago period, Ajanta Pharma said in a BSE filing.
"We have established strong sales and marketing network in select international markets which continue to perform well and generate demand for our branded generics.
"However, the currency devaluation and scarcity of forex availability in few emerging markets limited us to achieve our full potential," Ajanta Pharma Joint Managing Director Rajesh Agrawal said.
Next Story